Developer of rare-disease drugs gets $4.6M boost

05/17/2013 | American City Business Journals

A Series A funding round has brought in $4.6 million for Callidus Biopharma, a development-stage biotech firm specializing in rare-disease drugs. The Pennsylvania-based company plans to use the proceeds mainly to speed up preclinical development of its drug candidates for lysosomal storage disorders, including Pompe and Gaucher diseases. Money also will go toward the launch of the firm's proprietary protein-expression technology.

View Full Article in:

American City Business Journals

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Consumer Directed Health Plan (CDH) Product Offering Manager
Blue Cross Blue Shield MA
Quincy, MA
ISHN - Chief Compliance Officer
Mountain States Health Alliance
Johnson City, TN
Actuary
Meridian Health Plan
Detroit, MI
President/Chief Executive Officer
MedCost
Winston-Salem, NC
Director, Payer Marketing
Avalere Health
Washington, DC